Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.16 Bil Enterprise Value: 9.58 Bil PE Ratio: 106.36 PB Ratio: 2.73 GF Score: 85/100

Qiagen NV at Morgan Stanley Healthcare Conference Transcript

Sep 11, 2019 / 03:05PM GMT
Release Date Price: €31.62 (+2.30%)
John Gilardi
QIAGEN N.V. - VP of Corporate Communications & IR

Okay. So we're ready to get started. I'm John Gilardi from QIAGEN, and joining me on the stage here is Roland Sackers, our Chief Financial Officer. We're going to do a Q&A session. I'm going to ask Roland some questions. And then at the same time, hopefully, get some questions from the audience. But I'm going to start off with just a 2-minute elevator speech on QIAGEN, what we do and help bring people up to speed on QIAGEN.

So what QIAGEN does is really encapsulated by the phrase Sample to Insight. What we do is we help our customers, more than 0.5 million worldwide, to be able to go and take any biological sample, whether it's plant, tissue, plasma, whatever it is that contains DNA, RNA, the building blocks of life, and be able to isolate and purify the DNA, RNA out of that sample and then end up with a nucleic acid. That's what we call sample technologies.

We then offer a range of products to do -- interrogate that sample, to get the results, to get the insights that customers are looking for. Those are called

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot